(King of Prussia, PA; May 14, 2015) - Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, will open a new, state-of-the-art clinical supplies facility in Frankfurt, Germany, in June.
The current good manufacturing practice (cGMP)-compliant facility will triple Theorem’s current clinical supplies capacity, with space for 2,700 square meters of ambient (15 to 25°C) and refrigerated (2 to 8°C) space. The opening also positions Theorem’s clinical supplies hub near the Frankfurt Airport, a major transportation hub.
“We’re excited to have the additional manufacturing and warehousing space and, more importantly, an infrastructure to deliver the flexibility our clients rely on,” said John Potthoff, Theorem president and CEO. “The new facility will enhance speed and scalability while preserving the versatility of our supply solutions.”
Theorem packages, labels, stores, distributes and reclaims pre-randomized study drugs and medical devices for studies worldwide. Theorem also provides qualified person services, as well as a range of temperature-controlled transport and logistics solutions, to facilitate the supply of global clinical trials. The launch of the new facility will strengthen current practices - such as its 24/7/365 storage, continuous monitoring and backup - and provides space for future service expansion.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.